Trial Profile

A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prexasertib (Primary) ; Ralimetinib (Primary)
Indications Colon cancer; Non-small cell lung cancer
Focus Adverse reactions
Sponsors Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

09 Nov 2019 Results published in the Investigational New Drugs.
31 Aug 2017 Status changed from recruiting to completed.
09 Sep 2016 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com